Tags : Rizmoic

Sandoz Signs a Commercialization Agreement with Shionogi for Rizmoic (naldemedine)

Shots: Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany, UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s manufacturing & development The focus of the agreement is to enhance Sandoz’s anti-pain portfolio for minimizing the side-effects of opioid use in Europe Rizmoic (naldemedine,0.2mg) […]Read More